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Abstract. The aim of the present study was to determine the expression of vascular endothelial growth factor (VEGF)
family receptors (VEGFR) in placentas from pregnancies complicated by hypertensive disorders of different clinical sever-
ity. Placental tissue from women with gestational hypertension, pre-eclampsia, pre-eclampsia with haemolysis, elevated
liver enzymes and low platelets (HELLP syndrome) and normotensive women, as a control group, was examined. Immuno-
histochemical techniques, reverse transcription–polymerase chain reaction and western blot were used to evaluate receptor
expression. In cases with gestational hypertension, as well as in control cases, VEGFR-1 and VEGFR-3 immunoreactivity
was detected in all placental components, whereas in placentas from the pre-eclampsia and pre-eclampsia with HELLP
syndrome groups, VEGFR-1 and VEGFR-3 immunoreactivity was detected only in some portions of trophoblast and/or
some vessels and/or clusters of stromal cells. In the control group, VEGFR-2 immunoreactivity was observed only in
the vessels, whereas the hypertensive groups showed VEGF-2 immunoreactivity also in trophoblast and stromal cells.
The mRNA levels of the three receptors in the group with gestational hypertension were higher with respect to those in the
control group. Placentas from pregnancies with pre-eclampsia showed lowest mRNA expression levels, whereas placentas
from women with pre-eclampsia plus HELLP syndrome showed higher mRNA expression levels with respect to the three
other groups. Receptor protein levels were lower in pathological cases compared with levles in the control group. These
findings demonstrate a dysregulation of placental expression of VEGF family receptors related to the degree of clinical
severity of the hypertensive disorder.
Introduction
In normal pregnancies, the invasion of the maternal decidua and
transformation of the spiral arteries in low resistance vessels by
fetal trophoblast are essential for successful development of the
placenta (Pijinenborg 1994; Benirschke and Kaufmann 1995).
In pregnancies complicated by pre-eclampsia, this trophoblast
invasion is inadequate, resulting in poor placental perfusion and
fetal hypossia (Zhou et al. 1997; Damsky and Fisher 1998). This
induces a release of factors in the maternal circulation that may
cause vasoconstriction, hypertension, proteinuria and endothe-
lial dysfunction (Roberts and Redman 1993; Zhou et al. 1997;
Damsky and Fisher 1998).
Several vascular endothelial growth factors (VEGF), such as
VEGF-A, VEGF-B, VEGF-C, VEGF-D and placental growth
factor (PLGF), and their receptors have been shown to be
expressed in the placenta (Table 1).
The VEGF family and its receptors are likely to be involved
in the remodelling of uterine vessels, angiogenesis and the
regulation of trophoblast invasion, proliferation and differen-
tiation (Shore et al. 1997; Taylor et al. 1997; Torry and Torry
1997; Lash et al. 1999; Crocker et al. 2001; Gu et al. 2006).
Several studies have been undertaken investigating the
expression of the VEGF family and its receptors in placental
tissues of women with normal pregnancies (Cooper et al. 1995;
Clark et al. 1996; Cheung 1997; Shore et al. 1997; Dunk and
Ahmed 2001; Demir et al. 2004) and pregnancies complicated
by hypertensive disorders (Cooper et al. 1996; Lyall et al. 1997;
Cheng et al. 2001; El-Salahy et al. 2001; Helske et al. 2001;
Ranheim et al. 2001; Kumazaki et al. 2002; Zhou et al. 2002;
Tsatsaris et al. 2003). However, there are some discrepancies in
the data reported. In particular, in some studies a decrease in
the placental expression of VEGF-A and/or its receptors was
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Table 1. The vascular endothelial growth factor family and its receptors expressed in the placenta
Growth factors Molecular weight Receptors References
(kDa)
VEGF-A 45 VEGFR-1/Flt-1 De Vries et al. 1992; Terman et al. 1992;
VEGFR-2/Flk-1 Cheung 1997; Ni et al. 1997; Torry and
Torry 1997; Vuorela et al. 1997; Kingdom
et al. 2000; Favier and Corvol 2001
VEGF-B 48 VEGFR-1/Flt-1 De Vries et al. 1992; Klagsbrun and
D’Amore 1996; Vuorela et al. 1997
VEGF-C 24 VEGFR-2/Flk-1 Joukov et al. 1996; Klagsbrun and D’Amore
VEGFR-3/Flt-4 1996; Vuorela et al. 1997; Enholm et al. 1998
VEGF-D 16 VEGFR-2/Flk-1 Gu et al. 2006
VEGFR-3/Flt-4
PLGF 50 VEGFR-1/Flt-1 Maglione et al. 1991; De Vries et al. 1992
VEGF, vascular endothelial growth factor; PLGF, placental growth factor.
observed in pregnancies complicated by more or less severe
hypertensive disorders, such as pre-eclampsia and pre-eclampsia
with HELLP syndrome, compared with control pregnancies
(Cooper et al. 1996; Lyall et al. 1997; Zhou et al. 2002); other
studies have demonstrated either an increase in or no evidence
of abnormal placental VEGF and/or receptor expression in preg-
nancies complicated by hypertensive disorders (Cheng et al.
2001; Helske et al. 2001; Ranheim et al. 2001; Kumazaki et al.
2002; Tsatsaris et al. 2003).
In our previous study, VEGF-A expression was investi-
gated in placentas derived from pregnancies complicated by
hypertensive disorders with different clinical severity, such
as gestational hypertension, pre-eclampsia and pre-eclampsia
with haemolysis, elevated liver enzymes and low platelets
(HELLP syndrome). We used immunohistochemical and reverse
transcription–polymerase chain reaction (RT-PCR) techniques
to show the location and mRNA expression of this factor,
respectively (Sgambati et al. 2004). Moreover, we formed homo-
geneous groups of hypertensive disorders with a limited range
of gestational ages and randomly sampled the placental tissue
(to obtain material representative of the entire organ). This was
done in order to obtain a better determination of the expression
of VEGF-A in the various hypertensive disorders, to clarify the
disagreement beetween the data reported in the literature and to
understand the role of VEGF-A in these pathologies. The data
showed different expression of placental VEGF-A according to
the degree of clinical severity of the hypertensive disorder.
In the present study, we wanted to investigate the expression
profile of VEGF family receptors in placentas from the same
types of cases investigated in our previous study. In order to per-
form a complete study of the expression of the receptors, we used
immunohistochemical and RT-PCR techniques, as well as the
western blot technique for a quantitative analysis of the receptors.
Materials and methods
Group classification
Three groups of women were considered: (1) women with preg-
nancies complicated by gestational hypertension (n= 30 cases);
(2) women with pregnancies complicated by pre-eclampsia
(n= 25 cases); (3) women with pregnancies complicated by
pre-eclampsia with HELLP syndrome (n= 24 cases). Women
with uncomplicated pregnancies (n= 20 cases) were examined
as the control group. The gestational age ranged between 35 and
38 weeks.
No women with chronic hypertension, renal disease, diabetes
or pregnancies complicated by intrauterine growth restriction
(IUGR) were included in the study. In all study groups, women
were delivered by Caesarean section. In the control group, the
Caesarean section was performed because of one of the following
indications: breech presentation, cephalopelvic disproportion or
psychological reasons.
Gestational hypertension was defined as persistent dias-
tolic blood pressure (DBP) above 90 mmHg and systolic
blood pressure (SBP) above 140 mmHg, in patients nor-
motensive before 20 weeks of gestation. The criteria for
the diagnosis of pre-eclampsia were DBP above 90 mmHg
and SBP above 140 mmHg, with oedema and proteinuria
greater than 0.3 g per 24 h, in patients normotensive before 20
weeks of gestation. The criteria for the diagnosis of HELLP
syndrome were: (1) haemolysis: abnormal peripheral blood
smear, total bilirubin ≥ 1.2 mg dL−1 and lactic dehydrogenase
(LDH) ≥ 600 U L−1; (2) elevated liver enzymes: serum aspar-
tate aminotransferase (AST) ≥ 70 U L−1; and (3) low platelets:
platelets count ≤ 100 000 µL−1.
Informed written consent was obtained from each patient
prior to their participation in the study.
Placenta collection
At delivery, the placentas were weighed and full thickness blocks
were obtained.A stratified random sampling procedure was used
to obtain 12 full-thickness blocks per organ. Six specimens were
immersed in neutral 4% buffered formalin solution for 12 h and
processed in a standard manner for the preparation of paraffin
blocks; sections (5 µm) were then obtained. Other specimens
were snap-frozen in liquid nitrogen and stored at −80◦C.
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Immunohistochemistry
Sections were treated according to the immunohistochem-
ical technique for detection of VEG receptor (VEGFR)-1,
VEGFR-2 and VEGFR-3. Briefly, endogenous peroxidase was
blocked by incubation of sections in 0.3% hydrogen peroxide.
Samples were incubated with blocking serum to reduce non-
specific reactions and then incubated with the primary antibody.
The following primary antibodies were used: polyclonal rabbit
anti-VEGFR-1 and monoclonal mouse anti-VEGFR-2 diluted
1 : 80 in phosphate-buffered saline (PBS) and polyclonal rabbit
anti-VEGFR-3 diluted 1 : 100 in PBS (Santa Cruz, Santa Cruz,
CA, USA; Kumazaki et al. 2002; Zhou et al. 2002; Demir et al.
2004; Kaushal et al. 2005). The subsequent steps of the proce-
dure were performed using the ABC Staining Systems kit (Santa
Cruz) according to the manufacturer’s instructions. Immuno-
reactive VEGFR-1, VEGFR-2 and VEGFR-3 were localised by
incubating sections in 0.7 mg mL−1 3,3′-diaminobenzidine and
0.7 mg mL−1 hydrogen peroxide in 0.06 m Tris-buffered saline
(TBS). Controls samples were obtained by omitting the primary
antibodies or by incubating the sections with non-specific IgG
at the same concentrations as the primary antibodies.
For each section, 10 fields were examined by an investigator
blinded to the group from which the tissue came and scored for
staining location in trophoblast, stromal cells, Hofbauer cells
and vessels.
All sections were treated with immunohistochemical tech-
niques for each antibody in the same batch to eliminate
inter-batch variations.
Evaluation of immunostaining intensity
For each section, the staining intensity of the three VEGF recep-
tors was evaluated in trophoblast, stromal cells, Hofbauer cells
and vessels. For this purpose, optical density (OD) was mea-
sured on grey scale images using a computerised image analysis
program (Image-Pro Plus version 4.5; Media Cybernetics, Sil-
ver Spring, MD, USA). The staining intensity was measured and
expressed in arbitrary transmission units standardised from 0 to
250, with 0 being the maximum staining and 250 equivalent to
no staining. Ten fields for each section, selected at random, were
examined. In each field, for each placental component, two types
of measurements were made: (1) a measurement of the intensity
of the reactive components only; and (2) a measurement of the
intensity of all the components (reactive and not reactive).
Semiquantitative RT-PCR
For RT-PCR, total RNA was extracted from frozen specimens
using TriReagent (Sigma, Milan, Italy) according to the manu-
facturer’s instructions. The final total RNA pellet was suspended
in 30 µL diethyl pyrocarbonate-treated water and 2 µL was
used for the spectrophotometric determination of RNA con-
centrations at 260 nm and RNA quality (260 : 280 nm ratio).
An equal amount of total RNA (1 µg) from each sample was
reverse transcribed and amplified in a total volume of 50 µL
using the SuperScript One Step RT-PCR System with Plat-
inum Taq DNA (Invitrogen, Milan, Italy). Placental VEGFR-1,
VEGFR-2 andVEGFR-3 primer sequences were designed on the
basis of the published sequences (GeneBank accession numbers
Table 2. Vascular endothelial growth factor receptor (VEGFR)-1,
VEGFR-2, VEGFR-3 and β-actin sequence of primers and amplicons
size for reverse transcription–polymerase chain reaction analysis
Primers Amplicon size (bp)
VEGFR-1 5′-GGCTCTGTGGAAAGTTCAGC-3′ 223
5′-GCTCACACTGCTCATCCAAA-3′
VEGFR-2 5′-GTGACCAACATGGAGTCGTG-3′ 218
5′-TGCTTCACAGAAGACCATGC-3′
VEGFR-3 5′-GAGACAAGGACAGCGAGGAC-3′ 186
5′-TCACGAACACGTAGGAGCTG-3′
β-Actin 5′-GGACTTCGAGCAAGAGATGG-3′ 234
5′-AGCACTGTGTTGGCGTACCAG-3′
NM_002019, NM_002253 and NM_182925, respectively). The
forward and reverse primers and the expected product size for
each receptor are given in Table 2.
All RT-PCR were normalised with β-actin (GenBank acces-
sion no. NM_001101; Table 2) and the optimal PCR cycles
within linear ranges were determined (data not shown).
Placental VEGFR-1, VEGFR-2, VEGFR-3 and β-actin were
reverse transcribed by performing one cycle of 55◦C for 30 min
and 94◦C for 2 min. The PCR was conducted immediately after
cDNA synthesis, under the following conditions: 40 cycles for
VEGFR receptors and 30 cycles for β-actin of 94◦C for 15 s
(denaturation), 54◦C for 30 s (annealing) and 68◦C for 1 min
(extension), followed by a final extension at 68◦C for 5 min. The
size of the predicted products was visualised with 1.0% agarose
gel electrophoresis and ethidium bromide staining. The amount
of RT-PCR products was determined by densitometric analy-
sis using Image J Analysis software, Scion Corporation, MD,
USA. Data are expressed as the mean ± s.e.m. of three values of
VEGF receptor amplification products normalised to the start-
ing total RNA volumes and in reference to the corresponding
β-actin values.
Western blot
Frozen placental tissues were thawed, minced with a razor
blade and homogenised on ice three times (20 s each), in
lysis buffer (50 mm TRIS-HCl (pH 7.0), 150 mm NaCl, 1.5 mm
EDTA, 0.5 mm dithiothreitol, 0.25% (v/v) sodium dodecyl sul-
fate (SDS), 1% (v/v) Triton X-100) supplemented with a pro-
tease inhibitor cocktail (Roche, Milan, Italy) containing 10%
phenylmethylsulfonyl fluoride (PMSF). Tissue homogenates
were centrifuged at 20 000g for 15 min at 4◦C and the super-
natant assayed for total protein content (Bradford 1976) and
stored at −80◦C. Samples containing equal amounts of protein
(30 µg) were separated on 4–12% gradient SDS–polyacrylamide
gel electrophoresis (PAGE) and transferred to nitrocellulose
membrane. Non-specific binding of antibodies was blocked
by 1 h incubation in 5% powdered skim milk in PBS + 0.1%
Tween-20 (PBST). After three washes with PBST, membranes
were incubated for 1 h with the following primary anti-
bodies: polyclonal rabbit anti-VEGFR-1, monoclonal mouse
anti-VEGFR-2 and polyclonal rabbit anti-VEGFR-3 (Santa
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Cruz) diluted 1 : 200 in PBST containing 5% milk. Subsequently,
membranes were incubated for 1 h with horseradish peroxidase-
conjugated secondary antibodies diluted 1 : 1000 (Santa Cruz).
Immunoreactivity was detected using the Opti4CN kit (BioRad,
Milan, Italy) according to the manufacturer’s instructions.
Densitometric analysis of the bands was performed using Image
J Analysis software. Data are expressed as the mean ± s.d. of
triplicate determinations in a representative experiment of two
independent experiments with similar results.
Statistical analysis
To compare clinical data among the study groups, analysis of
variance (ANOVA) was applied.
Statistical analysis of immunostaining was performed using
Student’s t-test. Then, the following differences were tested:
(1) differences between data obtained from a measurement
of the intensity of the reactive components only of the con-
trol group and those of the other groups; (2) differences
between data obtained from a measurement of the intensity
of all the components (reactive and unreactive) in each study
group. The reproducibility of measurements was assessed by
comparing measurements made by one observer at differ-
ent times and the measurements of two observers. Intra- and
interobserver coefficients of variation were 1.5% and 5.2%,
respectively.
Student’s t-test was used to estimate the levels of signifi-
cance of differences in VEGFR-1/β-actin, VEGFR-2/β-actin
and VEGFR-3/β-actin mRNA ratios, as well as protein lev-
els, between control placenta and placentas from women with
gestational hypertension, pre-eclampsia and pre-eclampsia with
HELLP syndrome.
Differences in mRNA expression and protein levels among
the pathological study groups were compared using analysis of
variance (ANOVA).
For each test, P < 0.05 was considered statistically
significant.
Table 3. Clinical details of the study groups
Values are the mean ± s.e.m.
Controla Hypertensionb Pre-eclampsiac Pre-eclampsia/HELLP
(n= 20) (n= 30) (n= 25) syndromed (n= 24)
Maternal age (years) 30.2 ± 7.4 31.0 ± 8.3 31.1 ± 5.7 30.3 ± 6.5
Gestation at delivery (weeks) 38.0 ± 1.3 37.8 ± 1.8 35.6 ± 4.3∗ 35.4 ± 3.8∗
Birthweight (g) 3480.1 ± 610.1 3310.4 ± 712.2 2760.5 ± 516.2∗ 2638.1 ± 605.3∗
Placental weight (g) 618.8 ± 80.1 524.4 ± 59.1∗ 451.3 ± 65.1∗ 440.2 ± 58.5∗
Primigravida (n) 12 10 9 10
Smokers (n) 4 12 4 3
Pregnancy BMI (kg m−2) 22.4 ± 3.6 24.8 ± 3.2 24.3 ± 3.0 24.5 ± 4.3
Blood pressure at delivery (mmHg)
Systolic 111.2 ± 9.3 148.8 ± 9.1∗ 156.1 ± 9.2∗ 148.5 ± 10.1∗
Diastolic 65.7 ± 8.2 97.3 ± 6.5∗ 102.3 ± 9.4∗ 98.1 ± 8.2∗
For gestation at delivery and birthweight, c, d v. a, b = ∗P < 0.01. For placental weight, c, d v. a, b and b v. a = ∗P < 0.01; For systolic
and diastolic blood pressure at delivery, b, d v. a, c v. a, b and c v. a = ∗P < 0.01.
BMI, body mass index; pre-eclampsia/HELLP syndrome, pre-eclampsia with haemolysis, elevated liver enzymes and low platelets.
Results
Clinical details
The clinical details of the women whose placentas were used in
the present study are given in Table 3. Mean weeks of gestation
and mean birthweight at delivery were significantly lower in the
cases with pre-eclampsia and pre-eclampsia with HELLP syn-
drome compared with the other groups. Mean placental weight
was significantly lower in the pathological groups compared with
the control group. Mean pressure (SBP and DBP) was statisti-
cally higher in pathological cases compared with the control
cases.There were no significant differences between groups with
respect to the other clinical data.
Immunohistochemical analysis
The study was limited to the chorionic intermediate and terminal
villi.
Immunolocation
Results of immunostaining for VEGFR-1, VEGFR-2 and
VEGFR-3 in the placenta are given in Table 4.
VEGFR-1
In the control group, the trophoblast, endothelial cells of the
vessels, stromal cells and Hofbauer cells showed immunoreac-
tivity for VEGFR-1 (Fig. 1a).
In cases of hypertensive disorders, all placental components
were immunoreactive for VEGFR-1 (Fig. 1b), although in the
pre-eclampsia (Fig. 1c) and pre-eclampsia with HELLP syn-
drome (Fig. 1d) groups, some portions of the trophoblast, the
endothelial cells of some vessels and clusters of stromal cells
did not show reactivity.
VEGFR-2
In the control group, only the endothelial cells of the vessels
showed immunoreactivity for VEGFR-2 (Fig. 2a).
In cases of gestational hypertension, the trophoblast,
endothelial cells of the vessels and stromal cells showed
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Table 4. Assessment of vascular endothelial growth factor receptor (VEGFR)-1, VEGFR-2 and VEGFR-3
immunostaining in the placenta
Study groups Trophoblast Vessels Stromal cells Hofbauer cells
R-1 R-2 R-3 R-1 R-2 R-3 R-1 R-2 R-3 R-1 R-2 R-3
Control + – + + + + + – + + – +
Hypertension + + + + + + + + + + – +
Pre-eclampsia +∗ +∗ +∗ +∗∗ + + +§ +§ + + – +
Pre-eclampsia/HELLP +∗ +∗ +∗ +∗∗ +∗∗ +∗∗ +§ +§ +§ + – +
syndrome
R-1, VEGFR-1; R-2, VEGFR-2; R-3, VEGFR-3; –, no reactivity; +, reactivity; ∗, reactivity in some tracts of
the trophoblast; ∗∗, reactivity in some vessels; §, reactivity in cell clusters; pre-eclampsia/HELLP syndrome, pre-
eclampsia with haemolysis, elevated liver enzymes and low platelets.
(a) (b)
(c) (d )
Fig. 1. Vascular endothelial growth factor receptor (VEGFR)-1 immunostaining in the placenta. (a) Control and (b) gestational hypertension at 37 weeks.
The trophoblast, vessels, stromal cells and Hofbauer cells (arrows) are reactive. (c) Pre-eclampsia and (d) pre-eclampsia with haemolysis, elevated liver
enzymes and low platelets (HELLP syndrome) at 36 weeks. Reactivity is observable in some portions of the trophoblast, in some vessels, in clusters of stromal
cells and in Hofbauer cells (arrows). Scale bar = 25 µm.
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(a) (b)
(c) (d )
Fig. 2. Vascular endothelial growth factor receptor (VEGFR)-2 immunostaining in the placenta. (a) Control at 38 weeks. Reactivity is observable in the
vessels. (b) Gestational hypertension at 38 weeks. The trophoblast, vessels and stromal cells are reactive. (c) Pre-eclampsia at 37 weeks. Some portions of
the trophoblast, vessels and clusters of stromal cells show reactivity. (d) Pre-eclampsia with haemolysis, elevated liver enzymes and low platelets (HELLP
syndrome) at 36 weeks. Some portions of the trophoblast, some vessels and clusters of stromal cells are reactive. Scale bar = 25 µm.
reactivity (Fig. 2b). In cases of pre-eclampsia, some por-
tions of trophoblast, the endothelial cells of all vessels and
clusters of stromal cells were immunoreactive for VEGFR-2
(Fig. 2c). Cases of pre-eclampsia with HELLP syndrome showed
immunoreactivity forVEGFR-2 only in some portions of the tro-
phoblast, in endothelial cells of some vessels and in clusters of
stromal cells (Fig. 2d).
VEGFR-3
In the control group, all placental components were
immunoreactive for VEGFR-3 (Fig. 3a).
In cases of gestational hypertension (Fig. 3b) and
pre-eclampsia (Fig. 3c), all placental components showed
immunoreactivity for VEGFR-3, although in cases of pre-
eclampsia some portions of the trophoblast were not reactive. In
cases of pre-eclampsia with HELLP syndrome, some portions
of the trophoblast, the endothelial cells of some vessels, clusters
of stromal cells and Hofbauer cells showed immunoreactivity
for VEGFR-3 (Fig. 3d).
Statistical analysis of immunoreactivity
Differences in data from the first type of measurement
between the control and pathological groups
The statistical analysis with regard to the first type of
measurement showed that the intensity of VEGFR-1 immuno-
reactivity of the trophoblast in all pathological cases and of
stromal cells in cases of pre-eclampsia and pre-eclampsia with
HELLP syndrome was lower (P < 0.05) compared with the
control group; the vessels, in all pathological cases and the
stromal cells in cases of gestational hypertension did not show
significant differences in reactivity compared with the control
group. The intensity of VEGFR-2 reactivity of the vessels in
all pathological cases was significantly lower (hypertension and
pre-eclampsia with HELLP syndrome P < 0.01; pre-eclampsia
P < 0.001) compared with the control group. The VEGFR-3
reactivity of the trophoblast, stromal cells and vessels was sig-
nificantly lower in cases of gestational hypertension (P < 0.05),
pre-eclampsia (P < 0.05) and pre-eclampsia with HELLP syn-
drome (trophoblast and stromal cells P < 0.05; vessel: P < 0.01).
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(a) (b)
(c) (d )
Fig. 3. Vascular endothelial growth factor receptor (VEGFR)-3 immunostaining in the placenta. (a) Control and (b) gestational hypertension at 38 weeks.
The trophoblast, vessels, stromal cells and Hofbauer cells (arrows) show reactivity. (c) Pre-eclampsia 37 weeks. Some portions of the trophoblast, vessels,
stromal cells and one Hofbauer cell (arrow) show reactivity. (d) Pre-eclampsia with haemolysis, elevated liver enzymes and low platelets (HELLP syndrome)
at 36 weeks. Reactivity is observable in some portions of the trophoblast, in some vessels, in clusters of stromal cells and in one Hofbauer cell (arrow). Scale
bar = 25 µm.
There were no significant difference in VEGFR-1 and VEGFR-
3 reactivity in Hofbauer cells between any of the pathological
cases and the control group.
Differences in data between the first and second types
of measurement in each group
With regard to the three receptors, the data obtained for all
components in the control and gestational hypertension groups,
as well as for the Hofbauer cells in all four study groups, there
were no significant differences found between the first and sec-
ond types of measurement. With regard to VEGFR-1, in cases of
pre-eclampsia and pre-eclampsia with HELLP syndrome, val-
ues obtained for trophoblast (P < 0.01), vessels (P < 0.001) and
stromal cells (P < 0.01) were significantly lower in the second
type of measurement compared with the first. With regard to
VEGFR-2, values obtained for the trophoblast and stromal cells
(P < 0.05) in cases of pre-eclampsia and for the trophoblast
(P < 0.01), vessels (P < 0.01) and stromal cells (P < 0.05) in
cases of pre-eclampsia with HELLP syndrome were significantly
lower in the second type of measurement compared with the first.
There were no significant differences in data obtained using the
two measurements for vessels in cases of pre-eclampsia. With
regard to VEGFR-3, values for the trophoblast (P < 0.001) in
cases of pre-eclampsia and the trophoblast (P < 0.001), vessels
(P < 0.01) and stromal cells (P < 0.05) in cases of pre-eclampsia
with HELLP syndrome were significantly lower in the second
type of measurement compared with the first; there were no sig-
nificant differences between the two measurements in terms of
data for vessels and stroma in cases of pre-eclampsia.
RT-PCR assay
VEGFR-1
Levels of placental VEGFR-1 mRNA were significantly
higher in cases of gestational hypertension and pre-eclampsia
with HELLP syndrome compared with control cases, whereas
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Fig. 4. Reverse transcription–polymerase chain reaction analysis of vascu-
lar endothelial growth factor receptor (VEGFR)-1, VEGFR-2 and VEGFR-3
mRNA levels in placental tissue. Total RNA (1 g) of control (lane 1; C),
hypertension (lane 2; h), pre-eclampsia (lane 3; p) and pre-eclampsia with
haemolysis, elevated liver enzymes and low platelets (HELLP syndrome;
lane 4; H) was reverse transcribed and amplified in parallel with the house-
keeping gene β-actin. The upper panels display representative agarose gels
showing VEGFR-1, VEGFR-2, VEGFR-3 and β-actin mRNA expression
levels in placental samples from the control and pathological groups. Data
are representative of at least three separate experiments. Histograms show
VEGFR-1, VEGFR-2 and VEGFR-3 mRNA levels determined by densito-
metric analysis; each bar represents the mean ± s.e.m. of three values of each
amplification product normalised to the starting total RNA volumes and in
reference to the corresponding β-actin values. ∗P < 0.05 for VEGFR-1 h, p
and H v. C (Student’s t-test); P < 0.05 for h v. p and H, and p v. H (ANOVA);
∗P < 0.05 for VEGFR-2 h, p and H v. C (Student’s t-test); P < 0.05 for h v.
p, and p v. H (ANOVA); ∗P < 0.05 for VEGFR-3 h, p and H v. C (Student’s
t-test); P < 0.05 h v. p and H, and p v. H (ANOVA).
they were lower in pre-eclampsia cases compared with control.
TheVEGFR-1 mRNA levels in cases of gestational hypertension
and pre-eclampsia were significantly lower compared with lev-
els in cases of pre-eclampsia with HELLP syndrome; VEGFR-1
mRNA levels in cases of pre-eclampsia were significantly lower
compared levels in cases of gestational hypertension (Fig. 4).
VEGFR-2
The mRNA levels of VEGFR-2 were significantly higher
in cases of gestational hypertension and pre-eclampsia with
HELLP syndrome compared with control, whereas they were
lower in cases of pre-eclampsia compared with control. The
mRNA levels of VEGFR-2 in cases of gestational hyper-
tension and pre-eclampsia with HELLP syndrome were sig-
nificantly higher compared with mRNA levels in cases of
pre-eclampsia; no significant differences were found with
respect to mRNA levels of VEGFR-2 in cases of gestational
hypertension compared with pre-eclampsia with HELLP
syndrome (Fig. 4).
VEGFR-3
The mRNA levels of VEGFR-3 in cases of gestational
hypertension were significantly higher compared with con-
trol, whereas they were lower in cases of pre-eclampsia and
pre-eclampsia with HELLP syndrome cases compared with con-
trol. In cases of gestational hypertension, the mRNA levels of
VEGFR-3 were significantly higher compared levels in cases
of pre-eclampsia and pre-eclampsia with HELLP syndrome;
mRNA levels of VEGFR-3 in cases of pre-eclampsia were sig-
nificantly lower compared with levels in cases of pre-eclampsia
with HELLP syndrome (Fig. 4).
Western blot analysis
VEGFR-1 and VEGFR-2
Protein levels of VEGFR-1 and VEGFR-2 were significantly
lower in cases of gestational hypertension, pre-eclampsia and
pre-eclampsia with HELLP syndrome compared with control.
Protein levels of VEGFR-1 and VEGFR-2 in gestational hyper-
tension were significantly higher than in cases of pre-eclampsia
and pre-eclampsia with HELLP syndrome; no significant differ-
ences were found in the expression of VEGFR-1 and VEGFR-2
protein in cases of pre-eclampsia compared with pre-eclampsia
with HELLP syndrome (Fig. 5).
VEGFR-3
In cases of gestational hypertension, pre-eclampsia and pre-
eclampsia with HELLP syndrome, protein levels of VEGFR-3
were significantly lower compared with control. The protein
levels of VEGFR-3 in cases of gestational hypertension and
pre-eclampsia were significantly higher compared with cases
of pre-eclampsia with HELLP syndrome; no significant differ-
ences were found in protein levels between cases of gestational
hypertension and pre-eclampsia (Fig. 5).
Discussion
Our previous study on the expression of placental VEGF-A was
the first to be performed in pregnancies complicated by hyperten-
sive disorders with varying degrees of clinical severity (Sgambati
et al. 2004). In the present study, we wanted to determine, in the
same types of cases, the expression of the placental receptors that
mediate the functionality not only of VEGF-A, but also of other
components of the VEGF family (PLGF, VEGF-B, VEGF-C and
VEGF-D).
The findings obtained in the pathological cases were com-
pared with those observed in cases of normal pregnancies
considered to be the control group.
With regard to the control group, the immunohistochemistry
results showed that VEGFR-1 and VEGFR-3 were localised in
all placental components, whereas VEGFR-2 was detected only
in endothelial cells. These findings are in partial agreement with
those of previous investigations (Cooper et al. 1995; Clark et al.
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Fig. 5. Western blot analysis of placental tissue. Total protein (30 µg) from
control (lane 1; C), hypertension (lane 2; h), pre-eclampsia (lane 3; p) and
pre-eclampsia with haemolysis, elevated liver enzymes and low platelets
(HELLP syndrome; lane 4; H) placenta was loaded onto a 4–12% poly-
acrylamide gel, electrophoresed, blotted onto nitrocellulose and exposed to
anti-vascular endothelial growth factor receptor (VEGFR)-1, anti-VEGFR-2
and anti-VEGFR-3 antibodies. The position of molecular weight markers is
indicated. Bars represent the intensity of the bands, determined by densito-
metry. Data are expressed as the mean ± s.d. of triplicate determinations in
a representative experiment from two independent experiments with similar
results. ∗P < 0.05 for VEGFR-1 h, p and H v. C (Student’s t-test); P < 0.05
for h v. p and H (ANOVA); ∗P < 0.05 for VEGFR-2 h, p and H v. C (Student’s
t-test); P < 0.05 for h v. p and H (ANOVA); ∗P < 0.05 for VEGFR-3 h, p and
H v. C (Student’s t-test); P < 0.05 for h and p v. H (ANOVA).
1996; Cheung 1997; Shore et al. 1997; Dunk and Ahmed 2001;
Demir et al. 2004).
Regarding the location of VEGFR-1 and VEGFR-3, in
pre-eclampsia and, particularly, in pre-eclampsia with HELLP
syndrome, some portions of the trophoblast and/or some ves-
sels and/or clusters of stromal cells did not express these
receptors. Moreover, the intensity of immunoreactivity of some
positive components was significantly lower in all pathologi-
cal groups, particularly in the pre-eclampsia and pre-eclampsia
with HELLP syndrome groups. With regard to VEGFR-2 in the
pathological groups, its expression was detected not only in the
vessels, but also in the trophoblast and stroma, especially in
cases of gestational hypertension. However, the vessels of all
pathological groups showed a significantly lower intensity of
immunoreactivity compared with the control group.
The mRNA levels of the three receptors in the hyperten-
sion cases showed a statistically significant increase compared
with the control group. Cases of pre-eclampsia exhibited mRNA
levels of the three receptors that were significantly lower com-
pared with the other three groups. In cases of pre-eclampsia
with HELLP syndrome, VEGFR-1 mRNA levels were signifi-
cantly higher compared with the other groups;VEGFR-2 mRNA
levels were significantly increase compared with the control
and pre-eclampsia cases and VEGFR-3 mRNA levels were
significantly increased only compared with levels in cases of
pre-eclampsia.
Regarding protein expression levels, the data showed a
decrease in all VEGFR in the pathological groups, particularly
in the pre-eclampsia with HELLP syndrome group, compared
with control.
Some studies performed on placentas from pregnancies com-
plicated by pre-eclampsia with different degrees of clinical
severity or on placentas under various pathological conditions,
with all cases characterised by uteroplacental hypoperfusion,
have shown that the hypoxic environment upregulates VEGF-A
and its receptors, in particular VEGFR-1 (Helske et al. 2001;
Kumazaki et al. 2002; Tsatsaris et al. 2003). In contrast, other
authors have demonstrated that VEGF-A and VEGFR-1 are
downregulated in placentas of pregnancies with severe pre-
eclampsia and HELLP syndrome (Zhou et al. 2002) and studies
on the effect of hypoxia on placental tissue have demonstrated
that VEGF-A is upregulated, whereas VEGFR-1 is down-
regulated, by hypoxia (Ahmed et al. 2000). Moreover, some
studies have shown that an increase in VEGF-A, together with
other factors, may lead to the morphofunctional changes in pla-
cental tissue that characterise pre-eclampsia (Brockelsby et al.
2000; El-Salahy et al. 2001; Redman and Sargent 2001). From
these discordant data, it could be hypothesised that an over-
production of VEGF-A in a definite period of gestation may
lead to changes in placental tissue and that only the undamaged
placental components may continue to overproduce VEGF-A
(Sgambati et al. 2004). With regard to the data of the present
study, in placentas from pregnancies with hypertension, a com-
pensatory mechanism against the hypoxic environment occurs,
with an increasing production of the mRNA all three receptors,
as well as of the placental components that produce VEGFR-2.
Nevertheless, the increases in the expression of mRNA of the
receptors are not paralleled by increases in protein expression.
This could be due to slight functional changes of the placen-
tal components that lead to altered protein synthesis. In cases
of pre-eclampsia, a more severe complication characterised by
evident morphofunctional changes, only some placental com-
ponents may be able to produce the receptors. In cases of
pre-eclampsia with HELLP syndrome, which can be considered
a complication of pre-eclampsia or a completely different patho-
logical condition (Ben Aissia et al. 2001; Tsokos et al. 2002;
Zhou et al. 2002), there is probably greater damage of placen-
tal tissue triggered by an extremely hypoxic environment. This
may elicit mRNA overexpression (in particular for VEGFR-1
and VEGFR-2) by all placental components, as well as those
that are partially damaged. Nevertheless, only the few unaltered
placental components may be able to produce adequate protein
synthesis.
The findings of the present study are in partial agreement
with those of previous studies on the expression of VEGF recep-
tors in placentas of women with hypertensive disorders (Helske
et al. 2001; Kumazaki et al. 2002; Tsatsaris et al. 2003). The dis-
agreements may be due to the inclusion in the same study group
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of cases of hypertensive disorders with different degrees of clin-
ical severity, a wide range of gestational ages and to incorrect
sampling of the tissue. In the present study, as in our previ-
ous investigation (Sgambati et al. 2004), we attempted to make
homogeneous study groups with a limited range of gestational
ages and we performed random sampling to obtain material rep-
resentative of the entire organ in each case. Moreover, we used
different investigation methods to completely evaluate receptor
expression.
In conclusion, we have demonstrated that, in placental tissue
from pregnancies complicated by hypertensive disorders, there is
a dysregulation of the expression of the VEGF family receptors
1, 2 and 3 related to the different degrees of clinical severity.
Therefore, all three receptors, with altered expression levels, may
play an important role in the physiopathology of the placenta in
these disorders.
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